ZPHC Retatrutide 120mg kit 5 Vail

Retatrutide is an investigational drug that has not been approved by any regulatory agency worldwide (including the FDA, EMA, or Egyptian Drug Authority). Eli Lilly, the patent holder, explicitly states that retatrutide is legally available only through its own clinical trials. Any product sold outside those trials—including this ZPHC kit—is unapproved, unregulated, and potentially dangerous. The manufacturer warns that illicit retatrutide may contain unknown ingredients, harmful contaminants, or incorrect dosing . Beast Muscle does not manufacture, endorse, or verify the safety of this product. This listing is provided for informational/harm-reduction purposes only. Do not use without medical supervision.
ZPHC Retatrutide 120mg Kit (5 Vials × 24mg) is a research-grade triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. Supplied as a 5-vial kit totaling 120mg, this formulation is intended strictly for laboratory research purposes only. Retatrutide remains an investigational compound in Phase 3 clinical trials for obesity and metabolic disorders . Not for human consumption. Available for research acquisition in Egypt through Beast Muscle.

What Is ZPHC Retatrutide 120mg?
ZPHC Retatrutide 120mg is a multi-vial research kit containing five lyophilized vials, each containing 24mg of retatrutide peptide (total: 120mg). Retatrutide (development code LY3437943) is a triple hormone receptor agonist that simultaneously activates:
GLP-1 (glucagon-like peptide-1) — regulates appetite and satiety
GIP (glucose-dependent insulinotropic polypeptide) — supports insulin sensitivity
Glucagon — enhances energy expenditure and lipid oxidation
This triple mechanism distinguishes retatrutide from single agonists (semaglutide) and dual agonists (tirzepatide). In clinical trials, retatrutide demonstrated mean weight reductions of up to 24.2% at 48 weeks in Phase 2 data, with Phase 3 TRIUMPH-1 reporting up to 25.0% weight loss at 80 weeks at the 12mg dose .

Why Is This Product Listed as “Research Only”?
Retatrutide is not approved for human use anywhere in the world. The FDA has not authorized retatrutide, and the Egyptian Drug Authority has not registered any retatrutide product. ZPHC Retatrutide is supplied as a research chemical—a designation that explicitly excludes human or veterinary use. Researchers and laboratories may acquire it for controlled study, but no claims of safety, efficacy, or therapeutic benefit are made or implied for human consumption .

Clinical Context (For Research Reference)
Retatrutide is currently being studied in Eli Lilly’s TRIUMPH Phase 3 program for obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, and cardiovascular outcomes . Published Phase 3 data from TRIUMPH-1 (September 2026) reported:
Mean weight change: −17.6% (4mg), −23.7% (9mg), −25.0% (12mg) vs. −3.9% placebo at 80 weeks
Most common adverse events: Gastrointestinal (nausea, vomiting, diarrhea)

DIRECTIONS FOR RESEARCH USE
This product is NOT for human or animal consumption. The following is provided for laboratory handling reference only.
Storage upon receipt: Store lyophilized vials refrigerated (2–8°C), protected from light. Do not freeze.
Reconstitution (laboratory protocol): Add appropriate volume of bacteriostatic water or sterile diluent to achieve desired research concentration. Swirl gently; do not shake vigorously.
Handling: Use sterile syringes and aseptic technique in a controlled laboratory environment.
Documentation: Record lot number, reconstitution date, and storage conditions.

WARNINGS & DISCLAIMERS (MANDATORY READ)
Not Approved for Human Use. Retatrutide has not received marketing authorization from the FDA, EMA, Egyptian Drug Authority, or any global regulatory body. Eli Lilly states retatrutide is “legally available only through Lilly’s clinical trials” and that “anything sold to consumers outside of those trials is illegal” .
Serious Health Risks
Unregulated retatrutide products may contain:
Incorrect active ingredient or concentration
Harmful contaminants or endotoxins
Non-sterile manufacturing conditions 

Note About BEAST MUSCLE

We always strive to update product images on our store according to the versions available to us. There may be some changes in manufacturing, packaging, components, or external appearance from the producing companies. Shipments may carry an alternative shape or a newer version than shown in our store, but this does not reduce the guarantee of quality and originality of the products. We recommend that you read the warnings and instructions for each product before use and do not rely solely on the information provided by BEAST MUSCLE.